The interventional import of the Trikafta medication intended for the eight patients with cystic fibrosis who are in the most critical condition, has been officially approved by the Agency for Medicines MALMED.
This was confirmed for MIA by the director of the Agency, LjirimShabani, who pointed out that all the procedures for approving the import of the drug have been completed. The procedure still remains to be implemented.
